A post hoc analysis, performed on 23 patients for whom tumor tissue was available to determine KRAS status, showed that seven of 18 wt KRAS patients were progression-free at 12 weeks, while four of five KRAS mutant patients progressed during the same period. This evidence concerns the gene KRAS and neoplasm.